The selected candidates (hits) with anti-coronavirus activity will be subjected to study of their molecular mechanism of action, besides examining generation of potential drug-resistant virus variants.
Merck has signed an exclusive worldwide research collaboration and licence agreement with two Otsuka Pharmaceutical subsidiaries, Japanese Taiho Pharmaceutical and UK-based Astex Pharmaceuticals.